The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.
 
Sonam Puri
Consulting or Advisory Role - AstraZeneca (Inst); G1 Therapeutics (Inst)
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Kathleen Claire Kerrigan
Stock and Other Ownership Interests - bristol myers squibb (I)
Travel, Accommodations, Expenses - Flatiron Health
 
Shiven B. Patel
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Tersera; Total Health Conferencing
Research Funding - AstraZeneca (Inst); Merck (Inst); Takeda (Inst)
 
Andreas Seeber
Consulting or Advisory Role - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Florian Kocher
No Relationships to Disclose
 
DIPESH UPRETY
No Relationships to Disclose
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Zentalis
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
Amit Kulkarni
No Relationships to Disclose
 
Gilberto Lopes
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; E.R. Squibb Sons, LLC; Janssen; Pfizer
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; Guardant Health; Lilly; Merck; Novartis; Pfizer; Spectrum Pharmaceuticals; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology; GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Hossein Borghaei
Stock and Other Ownership Interests - Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Wallace L. Akerley
Consulting or Advisory Role - Calithera Biosciences
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Loxo (Inst)
Other Relationship - Lilly
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Genentech; Guardant Health; Inivata; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Pfizer; PharmaMar; Regeneron; Takeda
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Merus (Inst); Molecular Partners (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Trudy G. Oliver
Honoraria - Illumina; OncLive Clinical Congress Consultants; Pfizer
Patents, Royalties, Other Intellectual Property - Methods and compositions for identifying and treating patients with small cell lung cancer https://patents.google.com/patent/US20200010901A1/
Travel, Accommodations, Expenses - Pfizer
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Eisai; EMD Serono; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Wells Fargo; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical